Skip to content
Medical Health Aged Care

Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

Ferrer 2 mins read
BARCELONA, Spain--BUSINESS WIRE--

The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agreement with United Therapeutics Corporation (Nasdaq: UTHR) for Tyvaso® (treprostinil inhalation solution*) – a pharmaceutical drug-device combination product authorized for the treatment of WHO Group 3 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), and for WHO Group 1 Pulmonary Arterial Hypertension (PAH).

Both companies have signed the distribution rights for two new potential indications of the molecule, Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), two rare diseases characterized by scarring of lungs which results in difficulty for patients to breathe, leading to poor quality of life and even death. Current available treatments for IPF and PPF have only been shown to slow disease progression, whereas treprostinil inhalation solution could potentially offer a new treatment option in these patients.

“The pulmonary vascular and interstitial lung diseases field is very important for us”, said Oscar Pérez, Chief Scientific and Business Development Officer at Ferrer. “Strengthening our partnership with United Therapeutics Corporation can advance our purpose of using business to fight for social justice through the delivery of new solutions for people, families and caregivers living with devastating diseases”.

Under the expanded agreement, Ferrer has been appointed as the exclusive, worldwide distributor (except for the US, Canada, Japan, China, and Israel), to make this therapeutic option available upon approval for the treatment of IPF and PPF and keep delivering transformative solutions to the patients in need.

The announcement leverages Ferrer’s strong capabilities and expertise in pulmonary vascular and interstitial lung diseases and underscores both companies’ commitment to expanding global access to treprostinil inhalation solution for IPF and PPF patients, if approved.

Treprostinil inhalation solution is currently being assessed in three Phase 3 clinical trials: two in IPF patients (with over 1.000 subjects combined), and one in PPF patients (with 698 subjects), with a 52-week follow-up and collectively covering a global study geography.

* Treprostinil inhalation solution is a prostacyclin mimetic indicated for the treatment of Pulmonary arterial hypertension (PAH; WHO Group 1) and Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). Tyvaso® for PH-ILD is currently authorized in the US, Israel, Chile, Dominican Republic, and Argentina, and under regulatory review in Japan, and for WHO Group 1 Pulmonary Arterial Hypertension (PAH), currently authorized in the US, Israel, Argentina, Colombia, Japan, and Dominican Republic. Regarding the registration of Tyvaso® (treprostinil) inhalation solution for the treatment of PH-ILD, Ferrer has just obtained the marketing authorization in Chile and Dominican Republic and will focus on obtaining it in the United Kingdom as well. Further assessment of Tyvaso® PH-ILD for the European Union will continue.


Contact details:

Carlo Ferri
cferri@ferrer.com
+34 609 954 928

Media

More from this category

  • Medical Health Aged Care
  • 06/11/2024
  • 13:41
Australian College of Nursing

ACN Transcript – Scope of Practice Review – ACN National Director Professional Practice Karen Grace

MEDIA TRANSCRIPT 6 November 2024 ACN National Director Professional Practice Karen GraceScope of Practice Review - 2CC Canberra Breakfast STEPHEN CENATIEMPO: This week, the final report of what's called the Unleashing the Potential of Our Health Workforce - Scope of Practice Review was released by the Health Minister Mark Butler, and look, it seems to be mixed reviews to it. The Australian College of General Practitioners say that some of the recommendations could make it harder to get people into a GP office, while the Australian College of Nursing has welcomed the findings and recommendations of this report. Karen Grace…

  • Medical Health Aged Care
  • 06/11/2024
  • 09:32
Australian Nursing and Midwifery Federation (ANMF).

Nurses and midwives helping deliver new models of healthcare

The recommendations of the ‘Unleashing the Potential of our Health Workforce’ Scope of Practice Review’ Final Report (‘Report’), allowing highly-trained nurses, midwives and allied health professionals to best utilise their skills, education and extensive experience, provides an important new framework for the delivery of integrated, quality healthcare services across the community, according to the Australian Nursing and Midwifery Federation (ANMF). The ANMF welcomed several of the key reforms for the health workforce, including allowing NPs, remote area nurses and endorsed midwives, to make direct referrals for a wider range of procedures and services with MBS rebates, without the need for…

  • Indigenous, Medical Health Aged Care
  • 06/11/2024
  • 08:32
Monash University

How a discovery in the Merri Creek may save us from superbugs

A survey of a waterway on Wurundjeri land has led to the discovery of new viruses that kill the superbug Klebsiella. With estimates that…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.